Method of treating attention deficit disorders with d-threo methylphenidate

• US 5,908,850 A
• Filed: 04/02/1997
• Issued: 06/01/1999
• Est. Priority Date: 12/04/1995
• Status: Expired due to Term

• Current Assignee: Celgene Corporation (Bristol-Myers Squibb Company)
• Original Assignee: Celgene Corporation (Bristol-Myers Squibb Company)
• Inventors: Zeitlin, Andrew L., Dariani, Maghsoud M., Stirling, David I.
• Primary Examiner(s): HENLEY III, RAYMOND J
• Application Number:
  US08/827,230
• Time in Patent Office: 790 Days
• Field of Search: 514/315
• US Class Current: 514/315
• CPC Class Codes: A61K 31/4458 only substituted in position 2, e.g. methylphenidate

Abstract

Methods for treating Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, AIDS Dementia Complex and cognitive decline in HIV-AIDS while minimizing drug hypersensitivity, toxicity, side effects, euphoric effect, and drug abuse potential by administration of d-threo-methylphenidate or pharmaceutically acceptable salts thereof.

Claims

1. A method of treating at least one of Attention Deficit Disorder and Attention Deficit Hyperactivity Disorder and providing enhanced therapeutic activity, reduced side effects euphoric effect, or potential for drug abuse as compared to racemic threo methylphenidate, said method comprising administering to a human exhibiting symptoms of such disorder therapeutically effective amounts of D-threo methylphenidate or pharmaceutically acceptable salt thereof, substantially free of L-threo methylphenidate, on a daily basis.

2. The method according to claim 1 wherein the amount administered is 5 mg to 50 mg per day.

3. The method according to claim 1 wherein the amount of d-threo-methylphenidate or a pharmaceutically acceptable salt thereof is greater than 99% by weight.

4. The method according to claim 1 wherein said D-threo methylphenidate is administered together with a pharmaceutically acceptable carrier.